Skip to content
Well Researched

Glutathione

Glutathione (GSH) is a tripeptide composed of glutamate, cysteine, and glycine, often called the body's 'master antioxidant.' Found in virtually every cell, it plays critical roles in neutralizing…

Also known as: Master Antioxidant, Tripeptide, GSH

Typical Dose 200-400 mg
Storage Refrigerate reconstituted; store lyophilized powder away from light
How Often 1-2x weekly

Overview

Glutathione (GSH) is a tripeptide composed of glutamate, cysteine, and glycine, often called the body's 'master antioxidant.' Found in virtually every cell, it plays critical roles in neutralizing free radicals, detoxifying harmful substances, recycling other antioxidants (vitamins C and E), and supporting immune function. Glutathione levels decline with age and are depleted by stress, toxins, and certain diseases. Injectable forms bypass poor oral bioavailability to deliver glutathione directly to tissues.

Key Benefits

  • Master Antioxidant
  • Antioxidant Recycling
  • Phase II Liver Support

Direct delivery bypasses poor oral bioavailability. Rapidly increases plasma glutathione levels. Supports detoxification, immune function, and antioxidant defense systems.

Mechanism of Action

Glutathione directly neutralizes reactive oxygen species via its sulfhydryl group, conjugates toxins for excretion (Phase II detoxification), recycles vitamins C and E, and supports optimal lymphocyte function. The tripeptide's unique gamma peptide bond protects it from degradation by most peptidases.

Research Protocols Injectable

GoalDoseFrequencyRoute
General antioxidant support200-400 mg1-2x weeklySubcutaneous
Detoxification support400-600 mg2-3x weeklySubcutaneous
Immune support400-600 mg1-2x weeklySubcutaneous
Neurological support (Parkinson's research)1400 mg3x weeklySubcutaneous
Maintenance200 mg1x weeklySubcutaneous

Research protocols from published literature — not dosing recommendations.

Peptide Instructions Injectable

Supplies:

  • Glutathione vial (typically 200mg/mL concentration)
  • Insulin syringe (27-30 gauge) for IM/SubQ
  • Larger syringe for IV administration
  • Alcohol swabs
  • Sharps container for disposal

How to Reconstitute Injectable

  1. 1Most glutathione injections come pre-mixed - no reconstitution required
  2. 2If lyophilized: reconstitute with sterile water or bacteriostatic water per manufacturer instructions
  3. 3Inspect solution - should be clear and colorless to slightly yellow
  4. 4For IM/SubQ: Clean injection site with alcohol, draw prescribed dose
  5. 5For IV: Administer as slow push or dilute in normal saline for infusion
  6. 6IM injection: Deltoid or gluteal muscle at 90° angle
  7. 7SubQ injection: Abdomen or thigh at 45° angle
  8. 8Rotate injection sites to prevent tissue irritation

What to Expect Injectable

Week 1-2: Minimal noticeable effects. Plasma glutathione levels increase acutely after each injection but have short half-life (~14 minutes for reduced GSH).. Week 2-4: Some may notice improved energy or recovery. Detoxification processes are supported. Individual responses vary significantly.. Week 4-8: Potential improvements in skin appearance, immune resilience, or neurological symptoms depending on indication. Effects are often subtle.. Important: Glutathione is supportive therapy. Do not expect dramatic overnight changes. Benefits accumulate with consistent use over time.. Note: Skin lightening effects (if any) are modest and temporary, requiring ongoing treatment to maintain..

Side Effects & Safety

Generally well-tolerated when used appropriately. Injection site pain/stinging is common if pH is not properly balanced (optimal pH 6.0-7.0) - quality formulations should be pH-buffered close to physiological levels. Serious adverse events are rare but include anaphylaxis (especially IV) and potential hepatotoxicity with high doses. Gastrointestinal discomfort (bloating, cramping) may occur. May worsen asthma symptoms in susceptible individuals - avoid inhaled forms. Long-term use may reduce zinc levels - consider periodic zinc supplementation. Individuals with G6PD deficiency may be at risk for hemolysis with high doses. DO NOT use during chemotherapy without oncologist approval - may interfere with treatment. Avoid during pregnancy and breastfeeding - safety not established. Philippine FDA has issued warnings about IV glutathione for cosmetic skin lightening. Requires prescription from licensed healthcare provider.

Generally well-tolerated when used appropriately. Injection site pain/stinging is common if pH is not properly balanced (optimal pH 6.0-7.0) - quality formulations should be pH-buffered close to physiological levels. Serious adverse events are rare but include anaphylaxis (especially IV) and potential hepatotoxicity with high doses. Gastrointestinal discomfort (bloating, cramping) may occur. May worsen asthma symptoms in susceptible individuals - avoid inhaled forms. Long-term use may reduce zinc levels - consider periodic zinc supplementation. Individuals with G6PD deficiency may be at risk for hemolysis with high doses. DO NOT use during chemotherapy without oncologist approval - may interfere with treatment. Avoid during pregnancy and breastfeeding - safety not established. Philippine FDA has issued warnings about IV glutathione for cosmetic skin lightening. Requires prescription from licensed healthcare provider.

Community Insights

Glutathione should be stored at Refrigerate at 2-8°C (36-46°F). Protect from light. Do not freeze. Use within manufacturer's expiration date..

References

  1. Glutathione for Skin Lightening - Systematic Review · 2025
  2. Phase IIb Study of Intranasal Glutathione in Parkinson's Disease Mischley, L.K., Lau, R.C., Shankland, E.G., Wilbur, T.K., Padowski, J.M. · Journal of Parkinson's Disease 2017
  3. Glutathione synthesis Lu, S.C. · Biochimica et Biophysica Acta 2013
  4. Glutathione and immune function Droge, W., & Breitkreutz, R. · Proceedings of the Nutrition Society 2000
  5. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Sian, J., Dexter, D.T., Lees, A.J., et al. · Annals of Neurology 1994
  6. High-dose intravenous glutathione in man: Pharmacokinetics and effects on cyst(e)ine in plasma and urine Aebi, S., Assereto, R., Lauterburg, B.H. · European Journal of Clinical Investigation 1991
  7. High-dose IV Glutathione Pharmacokinetics - Aebi et al. · 0
  8. Glutathione in Parkinson's Disease - Substantia Nigra Depletion · 0
  9. Intranasal Glutathione Phase IIb Trial - Mischley et al. · 0
  10. Glutathione and Immune Function - Droge & Breitkreutz · 0
  11. GSH in Liver Detoxification - Phase II Conjugation · 0

Research reference only. Not medical advice.